You can helpexpand this article with text translated fromthe corresponding article in Japanese. (March 2020)Click [show] for important translation instructions.
View a machine-translated version of the Japanese article.
Machine translation, likeDeepL orGoogle Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consideradding a topic to this template: there are already 1,627 articles in themain category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
Youmust providecopyright attribution in theedit summary accompanying your translation by providing aninterlanguage link to the source of your translation. A model attribution edit summary isContent in this edit is translated from the existing Japanese Wikipedia article at [[:ja:大塚製薬]]; see its history for attribution.
You may also add the template{{Translated|ja|大塚製薬}} to thetalk page.
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社,Ōtsuka Seiyaku Kabushiki-gaisha) (TYO:4578), abbreviatedOPC, is apharmaceutical company headquartered inTokyo,Osaka andNaruto,Japan. The company was established August 10, 1964.
OPC's parent company Otsuka Holdings Co. Ltd. joined theTokyo Stock Exchange through aninitial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leaderTakeda Pharmaceutical Company.[1] The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]
In 1955, the company started afootball club called "Otsuka Pharmaceutical SC." In 2005 the name changed toTokushima Vortis. The club is based in Naruto.[2]
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company ofCG Roxane.[3]
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[4] This decision necessitated a revision in the terms of an agreement withUCB to end collaboration on immunology products while continuing collaboration in the CNS area.[5]
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-readyADHD drugcentanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[6]
In 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.[7]
